Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03406715
Title Combination Immunotherapy-Ipilimumab-Nivolumab-Dendritic Cell p53 Vac - Patients With Small Cell Lung Cancer (SCLC)
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors H. Lee Moffitt Cancer Center and Research Institute
Indications

lung small cell carcinoma

Therapies

Ad.p53-DC vaccine + Ipilimumab + Nivolumab

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.